Organic Active Ingredients TRIZ Cases

Auto-tandem palladium catalysis constructs selective Janus kinase inhibitors to reduce side effects from off-target inhibition.

Novel pyrazolo[3,4-d]pyrimidine compounds deliver potent HER2 inhibition with minimal EGFR cross-reactivity.

Combining omeprazole and fenbendazole reduces treatment duration from four weeks to fourteen days while minimizing side effects.

RNAi oligonucleotides suppress hepatitis B virus replication while avoiding renal toxicity in patients with severe kidney impairment.

Sulfobutyl ether beta-cyclodextrin forms an inclusion complex with meloxicam to overcome poor aqueous solubility and accelerate onset of pain relief.

Extruded spherical substrates vaporize aerosol agents through optimized heat transfer, eliminating liquid leakage and fire risks in delivery devices.

Continuous microreaction nitration eliminates explosive nitrogen triiodide formation and safety risks during copanlisib synthesis.

Nanoparticle-stabilized nanocapsules bypass endosomal entrapment and cytotoxicity by fusing with cell membranes to release siRNA directly into the cytosol.

Porous FDKP microparticles overcome digestive instability and lung barriers by adsorbing high drug content into small inhalable powder doses.

A composition containing paeoniflorin and albiflorin delays intrinsic aging by inhibiting MMP-1 expression.

Targeting p62 via PARP1 inhibition activates cancer-associated fibroblasts, while hyaluronidase degrades stroma to improve treatment outcomes.

Dual p38α/β inhibitors address limited efficacy and specificity in current cancer treatments by targeting the pathway effectively.

Hydrophilic polymers and solubilizing agents replace hydrophobic oils to improve estrogen release and ease of removal from applicators.

Amorphous solid dispersions improve bioavailability of hepatitis C protease inhibitors, resolving formulation complexity challenges.

Irreversible covalent binding at Cys797 overcomes T790M and C797S resistance mutations that block ATP-competitive inhibitors.

A stable pharmaceutical formulation combining metformin, pioglitazone, and an SGLT-2 inhibitor into a single dosage form.

Bacterial AHL analogs sensitize resistant tumor cells to TRAIL-induced apoptosis by modulating sphingolipid metabolism and inhibiting NF-kappaB signaling pathways.

eIF2B modulators attenuate the integrated stress response by preventing eIF2α phosphorylation from inhibiting translation initiation.

Low-temperature acidic auto-crosslinking produces high-viscosity hyaluronic acid gel without toxic agents.

Mechanical grinding of flavonoids with citric acid and L-arginine resolves poor water solubility, enabling clear solutions for pharmaceutical use.

A paclitaxel poly(amino acid) block copolymer formulation enables stable drug delivery without reconstitution.

Cleavable nucleotide analogues remove residual scars after dye excision, resolving polymerase recognition conflicts to extend sequencing read lengths.

Targeted compounds inhibit Nsp15 endoribonuclease activity, addressing the lack of effective therapeutic interventions for nidovirus diseases.

NAE1 inhibitors eliminate latent HIV reservoirs through apoptosis, resolving inflammation caused by lifelong antiretroviral therapy.

Polymer-conjugated liposomes incorporate glycosaminoglycan-modified lipids into their bilayer to enhance structural integrity and targeting precision.

An sGC stimulator boosts ATP levels and reduces oxidative stress by activating the nitric oxide-cGMP pathway in mitochondria.

Crystalline Form A of obeticholic acid resolves stability and purity contradictions via specific solvent crystallization for clinical use.

Mesoporous silica nanoparticles penetrate ocular barriers to deliver drugs to the posterior segment, reducing dosing frequency and improving bioavailability.

Antibody drug conjugates bind RAGE receptors to deliver cytotoxic payloads, resolving the trade-off between treatment specificity and harm to normal tissues.

Intracerebroventricular antisense oligonucleotides reduce MSH3 activity to delay nucleotide repeat expansion disorder progression.

Selective piperazine compounds target the 5-HT1A receptor to treat depression and anxiety while avoiding side effects like weight gain.

Sol-gel phase separation creates uniform mesoporous silica particles with controlled pore structures.

A guidewire and cannula system delivers therapeutic agents directly to target tissue.

Carbazole compounds inhibit bromodomain proteins by mimicking acetylated lysine residues, expanding therapeutic options for autoimmune diseases and cancers.

Plant cell bioencapsulation protects siRNA from degradation, resolving stability issues while maintaining high delivery efficiency.

A skin anti-aging agent combines low molecular DNA with soybean extract to activate dermal fibroblasts.

Piperazine derivatives selectively inhibit fatty acid synthase via local quality principles, reducing sebum production while preserving normal tissue function.

Elafibranor reduces liver enzyme levels to address UDCA treatment gaps in cholestatic diseases.

Synergistic benzodiazepine and HDAC inhibitor therapy reactivates latent HIV-1 while minimizing treatment side effects.

Lanostane derivatives from Poria extract treat cachexia by enhancing appetite and muscle maintenance without adverse side effects.

Multi-functional PPAR agonists resolve the contradiction between treatment effectiveness and managing multiple risk factors in metabolic syndrome.

Adenosine triphosphate enhances nutrient bioavailability via mucosal uptake, resolving formulation complexity while increasing C max and AUC levels.

A humanized antibody binds CD155 receptors to trigger receptor-mediated transcytosis across the blood-brain barrier.

A quinoline compound salt crystal form inhibits phosphoinositide 3-kinase activity.

Crystallizing the acid complex removes by-product IV, boosting yield and purity without column chromatography.

Sterol-derived compounds restore mitochondrial function to treat disorders linked to cellular energy deficits.